These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 31149002

  • 1. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
    Zheng J, Wang Z, Li E.
    Afr Health Sci; 2019 Mar; 19(1):1716-1726. PubMed ID: 31149002
    [Abstract] [Full Text] [Related]

  • 2. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I.
    Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
    [Abstract] [Full Text] [Related]

  • 3. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A.
    J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W.
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [Abstract] [Full Text] [Related]

  • 5. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study.
    Adair M, Bose R, Schmidt SN.
    Curr Med Res Opin; 2024 Sep; 40(9):1637-1645. PubMed ID: 39110846
    [Abstract] [Full Text] [Related]

  • 6. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G, Wang X, Ma D.
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [Abstract] [Full Text] [Related]

  • 7. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
    Iovieno N, Papakostas GI, Feeney A, Fava M, Mathew SJ, Iosifescu DI, Murrough JW, Macaluso M, Hock RS, Jha MK.
    J Clin Psychiatry; 2021 Jun 15; 82(4):. PubMed ID: 34133089
    [Abstract] [Full Text] [Related]

  • 8. Εfficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta‑analysis of randomized controlled trials.
    Gao S, Xie X, Fan L, Zhang D.
    Exp Ther Med; 2023 Nov 15; 26(5):515. PubMed ID: 37840562
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
    Fu J, Chen Y.
    Psychopharmacology (Berl); 2015 Jan 15; 232(1):7-16. PubMed ID: 24871704
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study.
    Di Nicola M, Adair M, Rieckmann A, Christensen M C.
    J Psychopharmacol; 2024 Jul 15; 38(7):615-623. PubMed ID: 39077889
    [Abstract] [Full Text] [Related]

  • 11. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG.
    J Affect Disord; 2016 Dec 15; 206():140-150. PubMed ID: 27474960
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.
    Wang J, Liu XF, Feng C, Bao Q, Fu HR.
    Int J Psychiatry Clin Pract; 2019 Nov 15; 23(4):245-250. PubMed ID: 29113521
    [Abstract] [Full Text] [Related]

  • 13. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
    Berhan A, Barker A.
    BMC Psychiatry; 2014 Sep 27; 14():276. PubMed ID: 25260373
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar 27; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR, Jacobsen PL, Chen Y.
    Curr Med Res Opin; 2013 Mar 27; 29(3):217-26. PubMed ID: 23252878
    [Abstract] [Full Text] [Related]

  • 16. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA, Loft H, Olsen CK.
    J Affect Disord; 2019 May 01; 250():35-42. PubMed ID: 30826492
    [Abstract] [Full Text] [Related]

  • 17. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A.
    CNS Spectr; 2019 Dec 01; 24(6):616-627. PubMed ID: 30802419
    [Abstract] [Full Text] [Related]

  • 18. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study.
    Vieta E, Florea I, Schmidt SN, Areberg J, Ettrup A.
    Int Clin Psychopharmacol; 2019 Jul 01; 34(4):153-160. PubMed ID: 31094901
    [Abstract] [Full Text] [Related]

  • 19. Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder.
    McIntyre RS, Necking O, Schmidt SN, Reines E.
    J Affect Disord; 2024 Oct 15; 363():430-435. PubMed ID: 39032712
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials.
    Li G, Wang X, Ma D.
    Neuropsychiatr Dis Treat; 2016 Oct 15; 12():523-31. PubMed ID: 27013879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.